Skip to main content

Advertisement

SpringerLink
Log in

Approach to Richter transformation of chronic lymphocytic leukemia in the era of novel therapies

  • Review Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Chronic lymphocytic leukemia (CLL) has a highly variable clinical course. About 2–10% of CLL patients develop aggressive histological transformation, most commonly to diffuse large B cell lymphoma (DLBCL), historically called Richter transformation (RT). Clinical features suggestive of RT include elevated LDH and non-specific symptoms such as fever, weight loss, and lymphadenopathy. 18-fluorodeoxyglucose (18-FDG) uptake is increased on PET scan (standardized uptake value max most commonly ≥ 10). PET/CT study can identify optimal site for excisional biopsy, which is the gold standard for RT diagnosis, as well as aid in disease staging and prognostication. In addition to clinical prognostic features such lactate dehydrogenase level, platelet count, and performance status, important predictors of poor outcome in RT are TP53 disruption and clonal relationship of DLBCL to underlying CLL. Chemoimmunotherapy constitutes the standard treatment for RT, followed by stem cell transplant (SCT) in eligible patients. However, the majority of patients do not proceed to allogeneic SCT, either due to inadequate disease control with initial therapy, poor performance status, or lack of donor availability. Overall outcome is dismal. Some novel agents under investigation, particularly PD-1 inhibitors, are showing clinical activity in Phase I and II trials. An ongoing incidence of RT has been noted in studies of previously treated patients receiving targeted therapies such as ibrutinib and venetoclax; the frequency of RT in patients initially treated with novel agents rather than chemoimmunotherapy will be important to determine with longer follow-up. This review focuses on the development, clinicopathologic features, and treatment of RT in the context of novel therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Rossi D, Spina V, Deambrogi C, Rasi S, Laurenti L, Stamatopoulos K, Arcaini L, Lucioni M, Rocque GB, Xu-Monette ZY, Visco C, Chang J, Chigrinova E, Forconi F, Marasca R, Besson C, Papadaki T, Paulli M, Larocca LM, Pileri SA, Gattei V, Bertoni F, Foa R, Young KH, Gaidano G (2011) The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. Blood 117(12):3391–3401. https://doi.org/10.1182/blood-2010-09-302174

    Article  CAS  PubMed  Google Scholar 

  2. Hatoum HA, Mahfouz RA, Otrock ZK, Hudaib AR, Taher AT, Shamseddine AI (2007) Acute myeloid leukemia with T-cell receptor gamma gene rearrangement occurring in a patient with chronic lymphocytic leukemia: a case report. Am J Hematol 82(1):69–72. https://doi.org/10.1002/ajh.20762

    Article  PubMed  Google Scholar 

  3. Jain P, O'Brien S (2012) Richter’s transformation in chronic lymphocytic leukemia. Oncology 26(12):1146–1152

    PubMed  Google Scholar 

  4. Parikh SA, Kay NE, Shanafelt TD (2014) How we treat Richter syndrome. Blood 123(11):1647–1657. https://doi.org/10.1182/blood-2013-11-516229

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Rossi D, Cerri M, Capello D, Deambrogi C, Rossi FM, Zucchetto A, De Paoli L, Cresta S, Rasi S, Spina V, Franceschetti S, Lunghi M, Vendramin C, Bomben R, Ramponi A, Monga G, Conconi A, Magnani C, Gattei V, Gaidano G (2008) Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome. Br J Haematol 142(2):202–215. https://doi.org/10.1111/j.1365-2141.2008.07166.x

    Article  CAS  PubMed  Google Scholar 

  6. Maurer C, Langerbeins P, Bahlo J, Cramer P, Fink AM, Pflug N, Engelke A, von Tresckow J, Kovacs G, Stilgenbauer S, Wendtner CM, Muller L, Ritgen M, Seiler T, Fischer K, Hallek M, Eichhorst B (2016) Effect of first-line treatment on second primary malignancies and Richte’s transformation in patients with CLL. Leukemia 30(10):2019–2025. https://doi.org/10.1038/leu.2016.113

    Article  CAS  PubMed  Google Scholar 

  7. Parikh SA, Shanafelt TD (2014) Risk factors for Richter syndrome in chronic lymphocytic leukemia. Curr Hematol Malig Rep 9(3):294–299. https://doi.org/10.1007/s11899-014-0223-4

    Article  PubMed  Google Scholar 

  8. Rasi S, Spina V, Bruscaggin A, Vaisitti T, Tripodo C, Forconi F, De Paoli L, Fangazio M, Sozzi E, Cencini E, Laurenti L, Marasca R, Visco C, Xu-Monette ZY, Gattei V, Young KH, Malavasi F, Deaglio S, Gaidano G, Rossi D (2011) A variant of the LRP4 gene affects the risk of chronic lymphocytic leukaemia transformation to Richter syndrome. Br J Haematol 152(3):284–294. https://doi.org/10.1111/j.1365-2141.2010.08482.x

    Article  CAS  PubMed  Google Scholar 

  9. Slager SL, Rabe KG, Kay NE, Cerhan JR, Shanafelt TD (2013) Heritable predisposition to Richter syndrome in patients with chronic lymphocytic leukemia. Blood 122(21):2867–2867

    Google Scholar 

  10. Rossi D, Rasi S, Fabbri G, Spina V, Fangazio M, Forconi F, Marasca R, Laurenti L, Bruscaggin A, Cerri M, Monti S, Cresta S, Fama R, De Paoli L, Bulian P, Gattei V, Guarini A, Deaglio S, Capello D, Rabadan R, Pasqualucci L, Dalla-Favera R, Foa R, Gaidano G (2012) Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. Blood 119(2):521–529. https://doi.org/10.1182/blood-2011-09-379966

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Rossi D, Gaidano G (2016) Richter syndrome: pathogenesis and management. Semin Oncol 43(2):311–319. https://doi.org/10.1053/j.seminoncol.2016.02.012

    Article  CAS  PubMed  Google Scholar 

  12. Strati P, Abruzzo LV, Wierda WG, O'Brien S, Ferrajoli A, Keating MJ (2015) Second cancers and Richter transformation are the leading causes of death in patients with trisomy 12 chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk 15(7):420–427. https://doi.org/10.1016/j.clml.2015.02.001

    Article  PubMed  PubMed Central  Google Scholar 

  13. Rossi D, Lobetti Bodoni C, Genuardi E, Monitillo L, Drandi D, Cerri M, Deambrogi C, Ricca I, Rocci A, Ferrero S, Bernocco E, Capello D, De Paoli L, Bergui L, Boi M, Omede P, Massaia M, Tarella C, Passera R, Boccadoro M, Gaidano G, Ladetto M (2009) Telomere length is an independent predictor of survival, treatment requirement and Richter’s syndrome transformation in chronic lymphocytic leukemia. Leukemia 23(6):1062–1072. https://doi.org/10.1038/leu.2008.399

    Article  CAS  PubMed  Google Scholar 

  14. Maddocks KJ, Ruppert AS, Lozanski G, Heerema NA, Zhao W, Abruzzo L, Lozanski A, Davis M, Gordon A, Smith LL, Mantel R, Jones JA, Flynn JM, Jaglowski SM, Andritsos LA, Awan F, Blum KA, Grever MR, Johnson AJ, Byrd JC, Woyach JA (2015) Etiology of Ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia. JAMA Oncol 1(1):80–87. https://doi.org/10.1001/jamaoncol.2014.218

    Article  PubMed  PubMed Central  Google Scholar 

  15. Burger JA, Landau DA, Taylor-Weiner A, Bozic I, Zhang H, Sarosiek K, Wang L, Stewart C, Fan J, Hoellenriegel J, Sivina M, Dubuc AM, Fraser C, Han Y, Li S, Livak KJ, Zou L, Wan Y, Konoplev S, Sougnez C, Brown JR, Abruzzo LV, Carter SL, Keating MJ, Davids MS, Wierda WG, Cibulskis K, Zenz T, Werner L, Dal Cin P, Kharchencko P, Neuberg D, Kantarjian H, Lander E, Gabriel S, O'Brien S, Letai A, Weitz DA, Nowak MA, Getz G, Wu CJ (2016) Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition. Nat Commun 7:11589. https://doi.org/10.1038/ncomms11589

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Vitale C, Ferrajoli A (2016) Richter syndrome in chronic lymphocytic leukemia. Curr Hematol Malig Rep 11(1):43–51. https://doi.org/10.1007/s11899-016-0300-y

    Article  PubMed  Google Scholar 

  17. Fabbri G, Khiabanian H, Holmes AB, Wang J, Messina M, Mullighan CG, Pasqualucci L, Rabadan R, Dalla-Favera R (2013) Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome. J Exp Med 210(11):2273–2288. https://doi.org/10.1084/jem.20131448

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Kadri S, Lee J, Fitzpatrick C, Galanina N, Sukhanova M, Venkataraman G, Sharma S, Long B, Petras K, Theissen M, Ming M, Kobzev Y, Kang W, Guo A, Wang W, Niu N, Weiner H, Thirman M, Stock W, Smith SM, Nabhan C, Segal JP, Lu P, Wang YL (2017) Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL. Blood Advances 1(12):715–727. https://doi.org/10.1182/bloodadvances.2016003632

    Article  Google Scholar 

  19. Rossi D, Rasi S, Spina V, Fangazio M, Monti S, Greco M, Ciardullo C, Fama R, Cresta S, Bruscaggin A, Laurenti L, Martini M, Musto P, Forconi F, Marasca R, Larocca LM, Foa R, Gaidano G (2012) Different impact of NOTCH1 and SF3B1 mutations on the risk of chronic lymphocytic leukemia transformation to Richter syndrome. Br J Haematol 158(3):426–429. https://doi.org/10.1111/j.1365-2141.2012.09155.x

    Article  CAS  PubMed  Google Scholar 

  20. Ahn IE, Underbayev C, Albitar A, Herman SEM, Tian X, Maric I, Arthur DC, Wake L, Pittaluga S, Yuan CM, Stetler-Stevenson M, Soto S, Valdez J, Nierman P, Lotter J, Xi L, Raffeld M, Farooqui M, Albitar M, Wiestner A (2017) Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia. Blood 129(11):1469–1479. https://doi.org/10.1182/blood-2016-06-719294

    Article  CAS  PubMed  Google Scholar 

  21. Serrano M, Hannon GJ, Beach D (1993) A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366(6456):704–707. https://doi.org/10.1038/366704a0

    Article  CAS  PubMed  Google Scholar 

  22. Zhang Y, Xiong Y, Yarbrough WG (1998) ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92(6):725–734

    Article  CAS  PubMed  Google Scholar 

  23. Chigrinova E, Rinaldi A, Kwee I, Rossi D, Rancoita PM, Strefford JC, Oscier D, Stamatopoulos K, Papadaki T, Berger F, Young KH, Murray F, Rosenquist R, Greiner TC, Chan WC, Orlandi EM, Lucioni M, Marasca R, Inghirami G, Ladetto M, Forconi F, Cogliatti S, Votavova H, Swerdlow SH, Stilgenbauer S, Piris MA, Matolcsy A, Spagnolo D, Nikitin E, Zamo A, Gattei V, Bhagat G, Ott G, Zucca E, Gaidano G, Bertoni F (2013) Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome. Blood 122(15):2673–2682. https://doi.org/10.1182/blood-2013-03-489518

    Article  CAS  PubMed  Google Scholar 

  24. Parikh SA, Rabe KG, Call TG, Zent CS, Habermann TM, Ding W, Leis JF, Schwager SM, Hanson CA, Macon WR, Kay NE, Slager SL, Shanafelt TD (2013) Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients. Br J Haematol 162(6):774–782. https://doi.org/10.1111/bjh.12458

    Article  PubMed  PubMed Central  Google Scholar 

  25. Solh M, Rai KR, Peterson BL, Kolitz JE, Appelbaum FR, Tallman MS, Belch A, Larson RA, Morrison VA (2013) The impact of initial fludarabine therapy on transformation to Richter syndrome or prolymphocytic leukemia in patients with chronic lymphocytic leukemia: analysis of an intergroup trial (CALGB 9011). Leukemia Lymphoma 54(2):252–254. https://doi.org/10.3109/10428194.2012.710327

    Article  CAS  PubMed  Google Scholar 

  26. Catovsky D, Richards S, Matutes E, Oscier D, Dyer MJ, Bezares RF, Pettitt AR, Hamblin T, Milligan DW, Child JA, Hamilton MS, Dearden CE, Smith AG, Bosanquet AG, Davis Z, Brito-Babapulle V, Else M, Wade R, Hillmen P, Group UKNCRIHOCS, Group NCLLW (2007) Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 trial): a randomised controlled trial. Lancet 370(9583):230–239. https://doi.org/10.1016/S0140-6736(07)61125-8

    Article  CAS  PubMed  Google Scholar 

  27. O'Brien SM, Kantarjian HM, Thomas DA, Cortes J, Giles FJ, Wierda WG, Koller CA, Ferrajoli A, Browning M, Lerner S, Albitar M, Keating MJ (2003) Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer 98(12):2657–2663. https://doi.org/10.1002/cncr.11871

    Article  PubMed  Google Scholar 

  28. Karlsson C, Norin S, Kimby E, Sander B, Porwit Macdonald A, Nilsson B, Johansson E, Mellstedt H, Lundin J, Osterborg A (2006) Alemtuzumab as first-line therapy for B-cell chronic lymphocytic leukemia: long-term follow-up of clinical effects, infectious complications and risk of Richter transformation. Leukemia 20(12):2204–2207. https://doi.org/10.1038/sj.leu.2404435

    Article  CAS  PubMed  Google Scholar 

  29. Kluin-Nelemans HC, Coenen JL, Boers JE, van Imhoff GW, Rosati S (2008) EBV-positive immunodeficiency lymphoma after alemtuzumab-CHOP therapy for peripheral T-cell lymphoma. Blood 112(4):1039–1041. https://doi.org/10.1182/blood-2008-02-138800

    Article  CAS  PubMed  Google Scholar 

  30. Lepretre S, Aurran T, Mahe B, Cazin B, Tournilhac O, Maisonneuve H, Casasnovas O, Delmer A, Leblond V, Royer B, Corront B, Chevret S, Delepine R, Vaudaux S, Van Den Neste E, Bene MC, Letestu R, Cymbalista F, Feugier P (2012) Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial. Blood 119(22):5104–5110. https://doi.org/10.1182/blood-2011-07-365437

    Article  CAS  PubMed  Google Scholar 

  31. O'Brien S, Furman RR, Coutre SE, Sharman JP, Burger JA, Blum KA, Grant B, Richards DA, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, Johnson AJ, Izumi R, Hamdy A, Chang BY, Graef T, Clow F, Buggy JJ, James DF, Byrd JC (2014) Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol 15(1):48–58. https://doi.org/10.1016/S1470-2045(13)70513-8

    Article  PubMed  Google Scholar 

  32. Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, Grant B, Sharman JP, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, Johnson AJ, Sukbuntherng J, Chang BY, Clow F, Hedrick E, Buggy JJ, James DF, O'Brien S (2013) Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 369(1):32–42. https://doi.org/10.1056/NEJMoa1215637

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Byrd JC, Brown JR, O'Brien S, Barrientos JC, Kay NE, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Devereux S, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Pocock C, Thornton P, Caligaris-Cappio F, Robak T, Delgado J, Schuster SJ, Montillo M, Schuh A, de Vos S, Gill D, Bloor A, Dearden C, Moreno C, Jones JJ, Chu AD, Fardis M, McGreivy J, Clow F, James DF, Hillmen P, Investigators R (2014) Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 371(3):213–223. https://doi.org/10.1056/NEJMoa1400376

    Article  PubMed  PubMed Central  Google Scholar 

  34. Barr P, Robak T, Owen CJ, Tedeschi A, Bairey O, Bartlett NL, Burger J, Hillmen P, Coutre S, Devereux S, Grosicki S, McCarthy H, Li J, Simpson D, Offner F, Moreno C, Zhou C, Styles L, James DF, Kipps TJ, Ghia P (2016) Updated efficacy and safety from the phase 3 Resonate-2 study: Ibrutinib as first-line treatment option in patients 65 years and older with chronic lymphocytic leukemia/small lymphocytic leukemia. Blood 128(22):234–234

    Google Scholar 

  35. O'Brien S, Jones JA, Coutre SE, Mato AR, Hillmen P, Tam C, Osterborg A, Siddiqi T, Thirman MJ, Furman RR, Ilhan O, Keating MJ, Call TG, Brown JR, Stevens-Brogan M, Li Y, Clow F, James DF, Chu AD, Hallek M, Stilgenbauer S (2016) Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. Lancet Oncol 17(10):1409–1418. https://doi.org/10.1016/S1470-2045(16)30212-1

    Article  PubMed  Google Scholar 

  36. Byrd JC, Harrington B, O'Brien S, Jones JA, Schuh A, Devereux S, Chaves J, Wierda WG, Awan FT, Brown JR, Hillmen P, Stephens DM, Ghia P, Barrientos JC, Pagel JM, Woyach J, Johnson D, Huang J, Wang X, Kaptein A, Lannutti BJ, Covey T, Fardis M, McGreivy J, Hamdy A, Rothbaum W, Izumi R, Diacovo TG, Johnson AJ, Furman RR (2016) Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med 374(4):323–332. https://doi.org/10.1056/NEJMoa1509981

    Article  CAS  PubMed  Google Scholar 

  37. O'Brien SM, Lamanna N, Kipps TJ, Flinn I, Zelenetz AD, Burger JA, Keating M, Mitra S, Holes L, Yu AS, Johnson DM, Miller LL, Kim Y, Dansey RD, Dubowy RL, Coutre SE (2015) A phase 2 study of idelalisib plus rituximab in treatment-naive older patients with chronic lymphocytic leukemia. Blood 126(25):2686–2694. https://doi.org/10.1182/blood-2015-03-630947

    Article  PubMed  PubMed Central  Google Scholar 

  38. Zelenetz AD, Barrientos JC, Brown JR, Coiffier B, Delgado J, Egyed M, Ghia P, Illes A, Jurczak W, Marlton P, Montillo M, Morschhauser F, Pristupa AS, Robak T, Sharman JP, Simpson D, Smolej L, Tausch E, Adewoye AH, Dreiling LK, Kim Y, Stilgenbauer S, Hillmen P (2017) Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol 18(3):297–311. https://doi.org/10.1016/S1470-2045(16)30671-4

    Article  CAS  PubMed  Google Scholar 

  39. Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, Kipps TJ, Anderson MA, Brown JR, Gressick L, Wong S, Dunbar M, Zhu M, Desai MB, Cerri E, Heitner Enschede S, Humerickhouse RA, Wierda WG, Seymour JF (2016) Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med 374(4):311–322. https://doi.org/10.1056/NEJMoa1513257

    Article  CAS  PubMed  Google Scholar 

  40. Stilgenbauer S, Eichhorst B, Schetelig J, Coutre S, Seymour JF, Munir T, Puvvada SD, Wendtner CM, Roberts AW, Jurczak W, Mulligan SP, Bottcher S, Mobasher M, Zhu M, Desai M, Chyla B, Verdugo M, Enschede SH, Cerri E, Humerickhouse R, Gordon G, Hallek M, Wierda WG (2016) Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol 17(6):768–778. https://doi.org/10.1016/S1470-2045(16)30019-5

    Article  CAS  PubMed  Google Scholar 

  41. Seymour JF, Ma S, Brander DM, Choi MY, Barrientos J, Davids MS, Anderson MA, Beaven AW, Rosen ST, Tam CS, Prine B, Agarwal SK, Munasinghe W, Zhu M, Lash LL, Desai M, Cerri E, Verdugo M, Kim SY, Humerickhouse RA, Gordon GB, Kipps TJ, Roberts AW (2017) Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. Lancet Oncol 18(2):230–240. https://doi.org/10.1016/S1470-2045(17)30012-8

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Jain P, Thompson PA, Keating M, Estrov Z, Ferrajoli A, Jain N, Kantarjian HM, Burger J, O'Brien SM, Wierda WG (2016) Causes of discontinuation and long-term outcomes of patients with CLL after discontinuing ibrutinib. Blood 128(22):4390–4390

    Google Scholar 

  43. Chan KL, Blombery P, Jones K, Lade S, Carney D, Tran H, Seymour JF, Tam CS (2016) Plasmablastic Richter transformation as a resistance mechanism for chronic lymphocytic leukaemia treated with BCR signalling inhibitors. Br J Haematol. https://doi.org/10.1111/bjh.14062

  44. Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, Barrientos JC, Zelenetz AD, Kipps TJ, Flinn I, Ghia P, Eradat H, Ervin T, Lamanna N, Coiffier B, Pettitt AR, Ma S, Stilgenbauer S, Cramer P, Aiello M, Johnson DM, Miller LL, Li D, Jahn TM, Dansey RD, Hallek M, O'Brien SM (2014) Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 370(11):997–1007. https://doi.org/10.1056/NEJMoa1315226

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Byrd JC, Furman RR, Coutre SE, Burger JA, Blum KA, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, Johnson AJ, Shaw Y, Bilotti E, Zhou C, James DF, O'Brien S (2015) Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood 125(16):2497–2506. https://doi.org/10.1182/blood-2014-10-606038

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, Bairey O, Hillmen P, Bartlett NL, Li J, Simpson D, Grosicki S, Devereux S, McCarthy H, Coutre S, Quach H, Gaidano G, Maslyak Z, Stevens DA, Janssens A, Offner F, Mayer J, O'Dwyer M, Hellmann A, Schuh A, Siddiqi T, Polliack A, Tam CS, Suri D, Cheng M, Clow F, Styles L, James DF, Kipps TJ, Investigators R (2015) Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med 373(25):2425–2437. https://doi.org/10.1056/NEJMoa1509388

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Swerdlow SH et al (2017) WHO classification of tumours of haematopoietic and lymphoid tissues. In: World Health Organization Classification of Tumours. IARC, Lyon

  48. Ronchi A, Marra L, Frigeri F, Botti G, Franco R, De Chiara A (2017) Richter syndrome with plasmablastic lymphoma at primary diagnosis: a case report with a review of the literature. Appl Immunohistochem Mol Morphol 25(6):e40–e45. https://doi.org/10.1097/pai.0000000000000441

  49. Evans AG, Rothberg PG, Burack WR, Huntington SF, Porter DL, Friedberg JW, Liesveld JL (2015) Evolution to plasmablastic lymphoma evades CD19-directed chimeric antigen receptor T cells. Br J Haematol. https://doi.org/10.1111/bjh.13562

  50. Trump DL, Mann RB, Phelps R, Roberts H, Conley CL (1980) Richter’s syndrome: diffuse histiocytic lymphoma in patients with chronic lymphocytic leukemia. A report of five cases and review of the literature. Am J Med 68(4):539–548

    Article  CAS  PubMed  Google Scholar 

  51. Shao H, Xi L, Raffeld M, Feldman AL, Ketterling RP, Knudson R, Rodriguez-Canales J, Hanson J, Pittaluga S, Jaffe ES (2011) Clonally related histiocytic/dendritic cell sarcoma and chronic lymphocytic leukemia/small lymphocytic lymphoma: a study of seven cases. Modern Pathol : An Off J United States Canadian Acad Pathol, Inc 24(11):1421–1432. https://doi.org/10.1038/modpathol.2011.102

    Article  CAS  Google Scholar 

  52. Chakhachiro Z, Yin CC, Abruzzo LV, Aladily TN, Barron LL, Banks HE, Thomas DA, Keating M, Medeiros LJ, Huh YO (2015) B-lymphoblastic leukemia in patients with chronic lymphocytic leukemia: a report of four cases. Am J Clin Pathol 144(2):333–340. https://doi.org/10.1309/AJCPXE5VMONMVLZ0

    Article  CAS  PubMed  Google Scholar 

  53. Fraser CR, Wang W, Gomez M, Zhang T, Mathew S, Furman RR, Knowles DM, Orazi A, Tam W (2009) Transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma to interdigitating dendritic cell sarcoma: evidence for transdifferentiation of the lymphoma clone. Am J Clin Pathol 132(6):928–939. https://doi.org/10.1309/AJCPWQ0I0DGXBMHO

    Article  CAS  PubMed  Google Scholar 

  54. Montgomery ND, Mathews SP (2016) Transformation in low-grade B-cell neoplasms. Surg Pathol Clin 9(1):79–92. https://doi.org/10.1016/j.path.2015.09.004

    Article  PubMed  Google Scholar 

  55. Parikh SA, Habermann TM, Chaffee KG, Call TG, Ding W, Leis JF, Macon WR, Schwager SM, Ristow KM, Porrata LF, Kay NE, Slager SL, Shanafelt TD (2015) Hodgkin transformation of chronic lymphocytic leukemia: incidence, outcomes, and comparison to de novo Hodgkin lymphoma. Am J Hematol 90(4):334–338. https://doi.org/10.1002/ajh.23939

    Article  PubMed  PubMed Central  Google Scholar 

  56. Tsimberidou AM, O'Brien S, Kantarjian HM, Koller C, Hagemeister FB, Fayad L, Lerner S, Bueso-Ramos CE, Keating MJ (2006) Hodgkin transformation of chronic lymphocytic leukemia: the MD Anderson Cancer Center experience. Cancer 107(6):1294–1302. https://doi.org/10.1002/cncr.22121

    Article  CAS  PubMed  Google Scholar 

  57. Bockorny B, Codreanu I, Dasanu CA (2012) Hodgkin lymphoma as Richter transformation in chronic lymphocytic leukaemia: a retrospective analysis of world literature. Br J Haematol 156(1):50–66. https://doi.org/10.1111/j.1365-2141.2011.08907.x

    Article  PubMed  Google Scholar 

  58. Tsimberidou AM, Keating MJ, Wierda WG (2007) Richter’s transformation in chronic lymphocytic leukemia. Curr Hematol Malig Rep 2(4):265–271. https://doi.org/10.1007/s11899-007-0036-9

    Article  PubMed  Google Scholar 

  59. Bruzzi JF, Macapinlac H, Tsimberidou AM, Truong MT, Keating MJ, Marom EM, Munden RF (2006) Detection of Richter’s transformation of chronic lymphocytic leukemia by PET/CT. J Nucl Med 47(8):1267–1273

    PubMed  Google Scholar 

  60. Michallet AS, Sesques P, Rabe KG, Itti E, Tordot J, Tychyj-Pinel C, Baseggio L, Subtil F, Salles G, Dupuis JM, Conte MJ (2016) An 18F-FDG-PET maximum standardized uptake value > 10 represents a novel valid marker for discerning Richter’s syndrome. Leuk Lymphoma 57(6):1474–1477. https://doi.org/10.3109/10428194.2015.1099643

    Article  PubMed  Google Scholar 

  61. Falchi L, Keating MJ, Marom EM, Truong MT, Schlette EJ, Sargent RL, Trinh L, Wang X, Smith SC, Jain N, Estrov Z, O'Brien S, Wierda WG, Lerner S, Ferrajoli A (2014) Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia. Blood 123(18):2783–2790. https://doi.org/10.1182/blood-2013-11-536169

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Mao Z, Quintanilla-Martinez L, Raffeld M, Richter M, Krugmann J, Burek C, Hartmann E, Rudiger T, Jaffe ES, Muller-Hermelink HK, Ott G, Fend F, Rosenwald A (2007) IgVH mutational status and clonality analysis of Richter’s transformation: diffuse large B-cell lymphoma and Hodgkin lymphoma in association with B-cell chronic lymphocytic leukemia (B-CLL) represent 2 different pathways of disease evolution. Am J Surg Pathol 31(10):1605–1614. https://doi.org/10.1097/PAS.0b013e31804bdaf8

    Article  PubMed  Google Scholar 

  63. Abrisqueta P, Pereira A, Rozman C, Aymerich M, Gine E, Moreno C, Muntanola A, Rozman M, Villamor N, Hodgson K, Campo E, Bosch F, Montserrat E (2009) Improving survival in patients with chronic lymphocytic leukemia (1980-2008): the Hospital Clinic of Barcelona experience. Blood 114(10):2044–2050. https://doi.org/10.1182/blood-2009-04-214346

    Article  CAS  PubMed  Google Scholar 

  64. Gine E, Martinez A, Villamor N, Lopez-Guillermo A, Camos M, Martinez D, Esteve J, Calvo X, Muntanola A, Abrisqueta P, Rozman M, Rozman C, Bosch F, Campo E, Montserrat E (2010) Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia (“accelerated” chronic lymphocytic leukemia) with aggressive clinical behavior. Haematologica 95(9):1526–1533. https://doi.org/10.3324/haematol.2010.022277

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Asano N, Yamamoto K, Tamaru J, Oyama T, Ishida F, Ohshima K, Yoshino T, Nakamura N, Mori S, Yoshie O, Shimoyama Y, Morishima Y, Kinoshita T, Nakamura S (2009) Age-related Epstein-Barr virus (EBV)-associated B-cell lymphoproliferative disorders: comparison with EBV-positive classic Hodgkin lymphoma in elderly patients. Blood 113(12):2629–2636. https://doi.org/10.1182/blood-2008-06-164806

    Article  CAS  PubMed  Google Scholar 

  66. Joseph L, Scott MA, Schichman SA, Zent CS (2001) Localized herpes simplex lymphadenitis mimicking large-cell (Richter’s) transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma. Am J Hematol 68(4):287–291

    Article  CAS  PubMed  Google Scholar 

  67. Parikh SA, Bhusal Y, Faderl SH, Wierda WG, O'Brien S, Kantarjian H, Adachi JA, Burger JA (2010) The great imitator: systemic nocardiosis mimicking Richter’s transformation in relapsed chronic lymphocytic leukemia. J Clin Oncol 28(35):e732–e734. https://doi.org/10.1200/JCO.2010.29.9792

    Article  PubMed  Google Scholar 

  68. Jain P, Hu S, Jabbour E, Takahashi K, Pemmaraju N, O'Brien S, Mulanovich VE, Estrov Z (2015) Disseminated histoplasmosis as pseudo Richter’s transformation in a patient with chronic lymphocytic leukemia. Am J Hematol 90(8):752–753. https://doi.org/10.1002/ajh.24029

    Article  PubMed  PubMed Central  Google Scholar 

  69. Brunner A, Kantner J, Tzankov A (2005) Granulomatous reactions cause symptoms or clinically imitate treatment resistance in small lymphocytic lymphoma/chronic lymphocytic leukaemia more frequently than in other non-Hodgkin lymphomas. J Clin Pathol 58(8):815–819. https://doi.org/10.1136/jcp.2004.023911

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Melo JV, Catovsky D, Galton DA (1986) The relationship between chronic lymphocytic leukaemia and prolymphocytic leukaemia. I. Clinical and laboratory features of 300 patients and characterization of an intermediate group. Br J Haematol 63(2):377–387

    Article  CAS  PubMed  Google Scholar 

  71. Reiniger L, Bodor C, Bognar A, Balogh Z, Csomor J, Szepesi A, Kopper L, Matolcsy A (2006) Richter’s and prolymphocytic transformation of chronic lymphocytic leukemia are associated with high mRNA expression of activation-induced cytidine deaminase and aberrant somatic hypermutation. Leukemia 20(6):1089–1095. https://doi.org/10.1038/sj.leu.2404183

    Article  CAS  PubMed  Google Scholar 

  72. Basu S, Alavi A (2016) PET-based personalized management in clinical oncology: an unavoidable path for the foreseeable future. PET Clinics 11(3):203–207. https://doi.org/10.1016/j.cpet.2016.03.002

    Article  PubMed  Google Scholar 

  73. Tsimberidou AM, O'Brien S, Khouri I, Giles FJ, Kantarjian HM, Champlin R, Wen S, Do KA, Smith SC, Lerner S, Freireich EJ, Keating MJ (2006) Clinical outcomes and prognostic factors in patients with Richter’s syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation. J Clin Oncol 24(15):2343–2351. https://doi.org/10.1200/JCO.2005.05.0187

    Article  CAS  PubMed  Google Scholar 

  74. Tadmor T, Shvidel L, Bairey O, Goldschmidt N, Ruchlemer R, Fineman R, Rahimi-Levene N, Herishanu Y, Yuklea M, Arad A, Aviv A, Polliack A, Israeli CLLSG (2014) Richter’s transformation to diffuse large B-cell lymphoma: a retrospective study reporting clinical data, outcome, and the benefit of adding rituximab to chemotherapy, from the Israeli CLL Study Group. Am J Hematol 89(11):E218–E222. https://doi.org/10.1002/ajh.23826

    Article  CAS  PubMed  Google Scholar 

  75. Jenke PEB, Busch R et al (2011) Cyclophosphamide, adriamycin, vincristine and prednisone plus rituximab (CHOP-R) in fludarabine (F) refractory chronic lymphocytic leukemia (CLL) or CLL with autoimmune cytopenia (AIC) or Richter’s transformation (RT): final analysis of a phase II study of the German CLL Study Group. ASH Annual Meeting Abstracts 118(21):2860

    Google Scholar 

  76. Tsimberidou AM, Wierda WG, Wen S, Plunkett W, O'Brien S, Kipps TJ, Jones JA, Badoux X, Kantarjian H, Keating MJ, Chronic Lymphocytic Leukemia Research C (2013) Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed/refractory chronic lymphocytic leukemia or Richter syndrome. Clin Lymphoma, Myeloma Leukemia 13(5):568–574. https://doi.org/10.1016/j.clml.2013.03.012

    Article  CAS  Google Scholar 

  77. Aydin S, Rossi D, Bergui L, D'Arena G, Ferrero E, Bonello L, Omede P, Novero D, Morabito F, Carbone A, Gaidano G, Malavasi F, Deaglio S (2008) CD38 gene polymorphism and chronic lymphocytic leukemia: a role in transformation to Richter syndrome? Blood 111(12):5646–5653. https://doi.org/10.1182/blood-2008-01-129726

    Article  CAS  PubMed  Google Scholar 

  78. Dabaja BS, O'Brien SM, Kantarjian HM, Cortes JE, Thomas DA, Albitar M, Schlette ES, Faderl S, Sarris A, Keating MJ, Giles FJ (2001) Fractionated cyclophosphamide, vincristine, liposomal daunorubicin (daunoXome), and dexamethasone (hyperCVXD) regimen in Richter’s syndrome. Leukemia Lymphoma 42(3):329–337. https://doi.org/10.3109/10428190109064589

    Article  CAS  PubMed  Google Scholar 

  79. Tsimberidou AM, Kantarjian HM, Cortes J, Thomas DA, Faderl S, Garcia-Manero G, Verstovsek S, Ferrajoli A, Wierda W, Alvarado Y, O'Brien SM, Albitar M, Keating MJ, Giles FJ (2003) Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia. Cancer 97(7):1711–1720. https://doi.org/10.1002/cncr.11238

    Article  CAS  PubMed  Google Scholar 

  80. Tsimberidou AM, Wierda WG, Plunkett W, Kurzrock R, O'Brien S, Wen S, Ferrajoli A, Ravandi-Kashani F, Garcia-Manero G, Estrov Z, Kipps TJ, Brown JR, Fiorentino A, Lerner S, Kantarjian HM, Keating MJ (2008) Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter’s syndrome or fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 26(2):196–203. https://doi.org/10.1200/JCO.2007.11.8513

    Article  CAS  PubMed  Google Scholar 

  81. Giles FJOBS (1996) KHSc-p, fludarabine, and arabinosyl cytosine (PFA) or cyclophosphamide, fludarabine and arabinosyl cytosine (CFA) in patients with Richter’s syndrome. Blood 88(Suppl 1):93a

    Google Scholar 

  82. Tsimberidou AM, O'Brien SM, Cortes JE, Faderl S, Andreeff M, Kantarjian HM, Keating MJ, Giles FJ (2002) Phase II study of fludarabine, cytarabine (Ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter's syndrome or refractory lymphoproliferative disorders. Leukemia Lymphoma 43(4):767–772. https://doi.org/10.1080/10428190290016872

    Article  CAS  PubMed  Google Scholar 

  83. Tsimberidou AM, Murray JL, O'Brien S, Wierda WG, Keating MJ (2004) Yttrium-90 ibritumomab tiuxetan radioimmunotherapy in Richter syndrome. Cancer 100(10):2195–2200. https://doi.org/10.1002/cncr.20252

    Article  CAS  PubMed  Google Scholar 

  84. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346(4):235–242. https://doi.org/10.1056/NEJMoa011795

    Article  CAS  PubMed  Google Scholar 

  85. Rossi D, Gaidano G (2013) Richter syndrome. Adv Exp Med Biol 792:173–191. https://doi.org/10.1007/978-1-4614-8051-8_8

    Article  CAS  PubMed  Google Scholar 

  86. Cwynarski K, van Biezen A, de Wreede L, Stilgenbauer S, Bunjes D, Metzner B, Koza V, Mohty M, Remes K, Russell N, Nagler A, Scholten M, de Witte T, Sureda A, Dreger P (2012) Autologous and allogeneic stem-cell transplantation for transformed chronic lymphocytic leukemia (Richter’s syndrome): a retrospective analysis from the chronic lymphocytic leukemia subcommittee of the chronic leukemia working party and lymphoma working party of the European Group for Blood and Marrow Transplantation. J Clin Oncol : Official J Am Soc Clin Oncol 30(18):2211–2217. https://doi.org/10.1200/JCO.2011.37.4108

    Article  Google Scholar 

  87. Wilson WH, Young RM, Schmitz R, Yang Y, Pittaluga S, Wright G, Lih CJ, Williams PM, Shaffer AL, Gerecitano J, de Vos S, Goy A, Kenkre VP, Barr PM, Blum KA, Shustov A, Advani R, Fowler NH, Vose JM, Elstrom RL, Habermann TM, Barrientos JC, McGreivy J, Fardis M, Chang BY, Clow F, Munneke B, Moussa D, Beaupre DM, Staudt LM (2015) Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med 21(8):922–926. https://doi.org/10.1038/nm.3884

    Article  CAS  PubMed  Google Scholar 

  88. Choi WW, Weisenburger DD, Greiner TC, Piris MA, Banham AH, Delabie J, Braziel RM, Geng H, Iqbal J, Lenz G, Vose JM, Hans CP, Fu K, Smith LM, Li M, Liu Z, Gascoyne RD, Rosenwald A, Ott G, Rimsza LM, Campo E, Jaffe ES, Jaye DL, Staudt LM, Chan WC (2009) A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res 15(17):5494–5502. https://doi.org/10.1158/1078-0432.CCR-09-0113

    Article  CAS  PubMed  Google Scholar 

  89. Giri S, Hahn A, Yaghmour G, Martin MG (2015) Ibrutinib has some activity in Richter’s syndrome. Blood Cancer J 5:e277. https://doi.org/10.1038/bcj.2014.98

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  90. Lamar Z, Kennedy L, Kennedy B, Lynch M, Goad A, Hurd D, McIver Z (2015) Ibrutinib and rituximab induced rapid response in refractory Richter syndrome. Clinical Case Reports 3(7):615–617. https://doi.org/10.1002/ccr3.269

    Article  PubMed  PubMed Central  Google Scholar 

  91. Tsang M, Shanafelt TD, Call TG, Ding W, Chanan-Khan A, Leis JF, Nowakowski GS, Bowen D, Conte M, Schwager SM, Slager SL, Kay NE, Hanson CA, Parikh SA (2015) The efficacy of ibrutinib in the treatment of Richter syndrome. Blood 125(10):1676–1678. https://doi.org/10.1182/blood-2014-12-610782

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  92. Hillmen P, Schuh A, Eyre TA, Pagel JM, Brown JR, Ghia P, Allan JN, Wierda W, Hamdy A, Huang J, Izumi R, Patel P, Wang MH, Byrd JC (2016) Acalabrutinib monotherapy in patients with Richter transformation from the phase 1/2 ACE-CL-001 clinical study. Blood 128(22):60–60

    Google Scholar 

  93. Harb W LN, Logsdon A, Steigelman M, Smith-Green H, Gaylor S et al (2014) The BCL2 targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 is active in patients with relapsed or refractory non-Hodgkin’s lymphoma. Paper presented at the American Society of hematology annual meeting.

  94. Anderson MA, Deng J, Seymour JF, Tam C, Kim SY, Fein J, Yu L, Brown JR, Westerman D, Si EG, Majewski IJ, Segal D, Heitner Enschede SL, Huang DC, Davids MS, Letai A, Roberts AW (2016) The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism. Blood 127(25):3215–3224. https://doi.org/10.1182/blood-2016-01-688796

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  95. Davids MS, Roberts AW, Seymour JF, Pagel JM, Kahl BS, Wierda WG, Puvvada S, Kipps TJ, Anderson MA, Salem AH, Dunbar M, Zhu M, Peale F, Ross JA, Gressick L, Desai M, Kim SY, Verdugo M, Humerickhouse RA, Gordon GB, Gerecitano JF (2017) Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma. J Clin Oncol 35(8):826–833. https://doi.org/10.1200/JCO.2016.70.4320

    Article  PubMed  Google Scholar 

  96. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, Lennon VA, Celis E, Chen L (2002) Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8(8):793–800. https://doi.org/10.1038/nm730

    Article  CAS  PubMed  Google Scholar 

  97. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N (2002) Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A 99(19):12293–12297. https://doi.org/10.1073/pnas.192461099

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  98. Hirano F, Kaneko K, Tamura H, Dong H, Wang S, Ichikawa M, Rietz C, Flies DB, Lau JS, Zhu G, Tamada K, Chen L (2005) Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res 65(3):1089–1096

    CAS  PubMed  Google Scholar 

  99. Hatae R, Chamoto K (2016) Immune checkpoint inhibitors targeting programmed cell death-1 (PD-1) in cancer therapy. [Rinsho ketsueki]. Japanese J Clin Hematol 57(10):2224–2231. 10.11406/rinketsu.57.2224

    Google Scholar 

  100. Iams WTP-IaP-IMCGwmocm-mp--i-a-iUS.

  101. Ding W, LaPlant BR, Call TG, Parikh SA, Leis JF, He R, Shanafelt TD, Sinha S, Le-Rademacher J, Feldman AL, Habermann TM, Witzig TE, Wiseman GA, Lin Y, Asmus E, Nowakowski GS, Conte MJ, Bowen DA, Aitken CN, Van Dyke DL, Greipp PT, Liu X, Wu X, Zhang H, Secreto CR, Tian S, Braggio E, Wellik LE, Micallef I, Viswanatha DS, Yan H, Chanan-Khan AA, Kay NE, Dong H, Ansell SM (2017) Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. Blood 129(26):3419–3427. https://doi.org/10.1182/blood-2017-02-765685

    Article  CAS  PubMed  Google Scholar 

  102. Jain N, Basu S, Thompson PA, Ohanian M, Ferrajoli A, Pemmaraju N, Cortes JE, Estrov Z, Burger JA, Neelapu SS, Lopez W, Thakral B, Bueso-Ramos CE, Blando J, O'Brien SM, Kantarjian HM, Allison J, Keating M, Sharma P, Wierda WG (2016) Nivolumab combined with ibrutinib for CLL and Richter transformation: a phase II trial. Blood 128(22):59–59

    Google Scholar 

  103. Lapalombella R, Sun Q, Williams K, Tangeman L, Jha S, Zhong Y, Goettl V, Mahoney E, Berglund C, Gupta S, Farmer A, Mani R, Johnson AJ, Lucas D, Mo X, Daelemans D, Sandanayaka V, Shechter S, McCauley D, Shacham S, Kauffman M, Chook YM, Byrd JC (2012) Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia. Blood 120(23):4621–4634. https://doi.org/10.1182/blood-2012-05-429506

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  104. Kuruvilla J, Savona M, Baz R, Mau-Sorensen M, Gabrail N, Garzon R, Stone R, Wang M, Savoie L, Martin P, Flinn I, Jacoby M, Unger TJ, Saint-Martin JR, Rashal T, Friedlander S, Carlson R, Kauffman M, Shacham S, Gutierrez M (2017) Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin’s lymphoma. Blood. https://doi.org/10.1182/blood-2016-11-750174

  105. Jaglowski SM, Jones JA, Nagar V, Flynn JM, Andritsos LA, Maddocks KJ, Woyach JA, Blum KA, Grever MR, Smucker K, Ruppert AS, Heerema NA, Lozanski G, Stefanos M, Munneke B, West JS, Neuenburg JK, James DF, Hall N, Johnson AJ, Byrd JC (2015) Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study. Blood 126(7):842–850. https://doi.org/10.1182/blood-2014-12-617522

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  106. Viardot A, Goebeler ME, Hess G, Neumann S, Pfreundschuh M, Adrian N, Zettl F, Libicher M, Sayehli C, Stieglmaier J, Zhang A, Nagorsen D, Bargou RC (2016) Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma. Blood 127(11):1410–1416. https://doi.org/10.1182/blood-2015-06-651380

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  107. Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO, Stetler-Stevenson M, Yang JC, Phan GQ, Hughes MS, Sherry RM, Raffeld M, Feldman S, Lu L, Li YF, Ngo LT, Goy A, Feldman T, Spaner DE, Wang ML, Chen CC, Kranick SM, Nath A, Nathan DA, Morton KE, Toomey MA, Rosenberg SA (2015) Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol 33(6):540–549. https://doi.org/10.1200/JCO.2014.56.2025

    Article  CAS  PubMed  Google Scholar 

  108. Neelapu SS, Locke FL, Bartlett NL, Lekakis L, Miklos D, Jacobson CA, Braunschweig I, Oluwole O, Siddiqi T, Lin Y, Timmerman J, Stiff PJ, Friedberg J, Flinn I, Goy A, Smith M, Deol A, Farooq U, McSweeney P, Munoz J, Avivi I, Castro JE, Westin JR, Chavez JC, Ghobadi A, Komanduri KV, Levy R, Jacobsen ED, Reagan P, Bot A, Rossi JM, Navale L, Jiang Y, Aycock JS, Elias M, Wiezorek J, Go WY (2016) Kte-C19 (anti-CD19 CAR T cells) induces complete remissions in patients with refractory diffuse large B-cell lymphoma (DLBCL): results from the pivotal phase 2 Zuma-1. Blood 128 (22):LBA-6-LBA-6

Download references

Author information

Authors and Affiliations

  1. Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1400 Holcombe Blvd, Houston, TX, 77030-4009, USA

    Maliha Khan & Philip A. Thompson

  2. Dow University of Health Sciences, Karachi, Pakistan

    Rabbia Siddiqi

Authors
  1. Maliha Khan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rabbia Siddiqi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Philip A. Thompson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Philip A. Thompson.

Ethics declarations

Conflict of interest

Dr. Thompson has been a consultant for and received honoraria from Pharmacyclics and has received research funding from Amgen and AbbVie.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Khan, M., Siddiqi, R. & Thompson, P.A. Approach to Richter transformation of chronic lymphocytic leukemia in the era of novel therapies. Ann Hematol 97, 1–15 (2018). https://doi.org/10.1007/s00277-017-3149-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-017-3149-9

Keywords

Search

Navigation